Kesios Therapeutics Ltd.
Targeting the NF-κB pathway in cancer drug discovery
This article was originally published in Start Up
The NF-κB pathway plays a key role in inflammation and immunity, but it is increasingly understood to be important in cancer. Kesios Therapeutics Ltd. and Imperial College London are working in parallel to develop therapeutics targeting the pathway for the treatment of cancer, and move them into clinical trials.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.